Hikma launches migraine injection treatment

Hikma Pharmaceuticals has launched its own version of an acute injected treatment for migraine headaches, dihydroergotamine mesylate.

West-Ward's Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

According to IMS Health, US sales of Dihydroergotamine Mesylate Injection, USP were approximately $34.8 million in the 12 months ending October 2017.

Riad Mechlaoui, Chief Executive Officer of Injectables said, "We are pleased to be adding Dihydroergotamine Mesylate Injection, USP to our Injectables portfolio in the US. We have a large portfolio of products and a pipeline of differentiated products to support future growth."

US sales of dihydroergotamine mesylate injection were roughly $34.8m in the 12 months to the end of October.

Hikma's West-Ward arm will market the injection as for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

"We have a large portfolio of products and a pipeline of differentiated products to support future growth," added Hikma's injectables chief Riad Mechlaoui.